J

Johnson & Johnson

Makes prescription drugs and medical devices

Business Compliance Manager - Emerging Markets EP

Full-TimePosted on 10/23/2026Deadline 11/6/26
PLN4.2k - PLN29.5k/mo+ Annual target bonus + Sales commissions
Expert
Bachelor's
Zagreb, Croatia+3 moreMore locations: Warsaw, Poland | Ljubljana, Slovenia | Prague, Czechia
HybridHybrid/office based; occasional regional and international travel. Other CEE locations are also permitted.
Risk & ComplianceRegulatory Compliance & Ethics

About the job

Requirements
  • A university degree is required.
  • Significant experience in healthcare compliance, professional education, contracting, business operations, commercial excellence, or related functions within the healthcare or medical device industry is preferred.
  • Demonstrated people leadership experience including coaching, development, and performance management is preferred.
  • Strong understanding of healthcare compliance requirements and associated business processes.
  • Experience managing regional or multi-country operations.
  • Strong project management and stakeholder management skills.
  • Excellent organizational, planning, and prioritization capabilities.
  • Strong analytical and problem-solving skills.
  • Excellent verbal and written English communication skills.
  • Advanced computer literacy and a digital mindset.
  • A high level of integrity and ethical standards.
  • Ability to influence and collaborate effectively across a complex matrix organization.
  • Proven ability to lead through ambiguity and drive change.
  • Experience within Johnson & Johnson MedTech is preferred.
  • Experience supporting Emerging Markets or multinational organizations is preferred.
  • Knowledge of HCCLife, SAP, Ariba, Lynx, and related compliance platforms is preferred.
  • Additional languages spoken within Emerging Markets are preferred.
  • Ability to manage multiple priorities across countries and functions.
  • Ability to work effectively in a complex matrix environment.
  • Occasional regional and international travel is required.
Responsibilities
  • Lead, coach, and develop a team of Business Compliance Specialists across Emerging Markets.
  • Establish performance objectives, development plans, and operational priorities for the team.
  • Ensure appropriate workload allocation, resource planning, and business continuity.
  • Foster a culture of accountability, collaboration, continuous improvement, and compliance excellence.
  • Drive talent development, succession planning, and capability building within the Business Compliance organization.
  • Serve as the primary Business Compliance lead for Emerging Markets EP.
  • Drive standardization, simplification, and harmonization of business compliance processes across markets and subclusters.
  • Develop and maintain regional governance, operating procedures, policies, process documentation, and best practices.
  • Ensure alignment with Healthcare Compliance, Legal, Finance, Procurement, and Professional Education requirements.
  • Establish and monitor key performance indicators and operational metrics to ensure effective service delivery and process performance.
  • Oversee compliant execution of educational courses, speaker programs, workshops, grants, sponsorships, and professional education activities.
  • Provide guidance and escalation support for complex or high-risk activities.
  • Ensure appropriate documentation, approvals, contracting, reporting, reconciliation, and audit readiness.
  • Partner with Professional Education, Commercial, and Healthcare Compliance teams to support business objectives while maintaining compliance with company policies.
  • Provide oversight of healthcare professional, healthcare organization, educational grant, sponsorship, and vendor contracting processes.
  • Ensure contracts and agreements are executed in accordance with internal policies and applicable regulations.
  • Monitor educational grant processes, documentation standards, reporting requirements, and reconciliation activities.
  • Act as an escalation point for complex contracting and compliance-related matters.
  • Oversee payment processes related to educational activities, grants, congresses, sponsorships, and professional education programs.
  • Ensure compliance with internal financial controls and governance requirements.
  • Monitor reconciliation activities, invoice management, cross-country charge processes, and audit preparedness.
  • Drive operational excellence through process optimization and automation initiatives.
  • Maintain direct operational involvement in selected CEE business compliance activities.
  • Support critical educational events, grants, contracts, and compliance processes where senior oversight is required.
  • Act as a subject matter expert and provide guidance to business stakeholders across CEE markets.
  • Build strong partnerships with Commercial Excellence, Professional Education, Healthcare Compliance, Finance, Procurement, Legal, and Human Resources.
  • Serve as a trusted advisor on business compliance processes, governance, and operational effectiveness.
  • Ensure proactive communication and alignment across multiple functions and countries.
Desired Qualifications
  • Significant experience in healthcare compliance, professional education, contracting, business operations, commercial excellence, or related functions within the healthcare or medical device industry.
  • Demonstrated people leadership experience including coaching, development, and performance management.
  • Experience within Johnson & Johnson MedTech.
  • Experience supporting Emerging Markets or multinational organizations.
  • Knowledge of HCCLife, SAP, Ariba, Lynx, and related compliance platforms.
  • Additional languages spoken within Emerging Markets.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.